<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CEDAX- ceftibuten dihydrate capsule </strong><br><strong>CEDAX- ceftibuten dihydrate suspension </strong><br>Sciele Pharma, Inc.<br></p></div>
<h1>CEDAX<span class="Sup">® </span><br>(ceftibuten capsules) <br>and <br>(ceftibuten for oral suspension)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">FOR ORAL USE ONLY</span></p>
<p><span class="Bold">PRODUCT INFORMATION</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">CEDAX (ceftibuten capsules) and (ceftibuten for oral suspension) contain the active ingredient ceftibuten as ceftibuten dihydrate. Ceftibuten dihydrate is a semisynthetic cephalosporin antibiotic for oral administration. Chemically, it is  (+)-(6R,7R)-7-[(Z)-2-(2-Amino-4-thiazolyl)-4-carboxycrotonamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, dihydrate. Its molecular formula is C<span class="Sub">15</span>H<span class="Sub">14</span>N<span class="Sub">4</span>O<span class="Sub">6</span>S<span class="Sub">2</span>•2H<span class="Sub">2</span>O. Its molecular weight is 446.43 as the dihydrate.</p>
<p>Ceftibuten dihydrate has the following structural formula:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2dd58c88-142f-41ad-bc31-0a4fff074970&amp;name=cedax-01.jpg"></div>
<p>CEDAX Capsules contain ceftibuten dihydrate equivalent to 400 mg of ceftibuten. Inactive ingredients contained in the capsule formulation include: magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. The capsule shell and/or band contains gelatin, sodium lauryl sulfate, titanium dioxide, and polysorbate 80. The capsule shell may also contain benzyl alcohol, sodium propionate, edetate calcium disodium, butylparaben, propylparaben, and methylparaben.</p>
<p>CEDAX Oral Suspension after reconstitution contains ceftibuten dihydrate equivalent to 90 mg of ceftibuten per 5 mL. CEDAX Oral Suspension is cherry flavored and contains the inactive ingredients: cherry flavoring, polysorbate 80, silicon dioxide, simethicone, sodium benzoate, sucrose (approximately 1 g/5 mL), titanium dioxide, and xanthan gum.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43682-4">
<a name="section-3.1"></a><p></p>
<h2>PHARMACOKINETICS</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.1"></a><p></p>
<h3>Absorption</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.1.1"></a><p></p>
<h4>CEDAX CAPSULES</h4>
<p class="First">Ceftibuten is rapidly absorbed after oral administration of CEDAX Capsules. The plasma concentrations and pharmacokinetic parameters of ceftibuten after a single 400-mg dose of CEDAX Capsules to 12 healthy adult male volunteers (20 to 39 years of age) are displayed in the table below. When CEDAX Capsules were administered once daily for 7 days, the average C<span class="Sub">max</span> was 17.9 µg/mL on day 7. Therefore, ceftibuten accumulation in plasma is about 20% at steady state.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.1.2"></a><p></p>
<h4>CEDAX ORAL SUSPENSION</h4>
<p class="First">Ceftibuten is rapidly absorbed after oral administration of CEDAX Oral Suspension. The plasma concentrations and pharmacokinetic parameters of ceftibuten after a single 9-mg/kg dose of CEDAX Oral Suspension to 32 fasting pediatric patients (6 months to 12 years of age) are displayed in the following table:</p>
<table width="90%">
<col align="center" valign="top" width="20%">
<col align="center" valign="middle" width="40%">
<col align="center" valign="middle" width="40%">
<thead><tr class="First Last">
<th class="Lrule" align="left">
<br>Parameter</th>
<th class="Lrule" align="center">Average Plasma Concentration (in µg/mL of ceftibuten after a single 400-mg dose) and Derived Pharmacokinetic Parameters (± 1 SD)<br>(n = 12 healthy adult males)</th>
<th class="Lrule Rrule" align="center">Average Plasma Concentration (in µg/mL of ceftibuten after a single 9-mg/kg dose) and Derived Pharmacokinetic Parameters (± 1 SD)<br>(n = 32 pediatric patients)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="center">1.0 h</td>
<td class="Lrule" align="center">6.1 (5.1)</td>
<td class="Lrule Rrule" align="center">9.3 (6.3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">1.5 h</td>
<td class="Lrule" align="center">9.9 (5.9)</td>
<td class="Lrule Rrule" align="center">8.6 (4.4)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">2.0 h</td>
<td class="Lrule" align="center">11.3 (5.2)</td>
<td class="Lrule Rrule" align="center">11.2 (4.6)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">3.0 h</td>
<td class="Lrule" align="center">13.3 (3.0)</td>
<td class="Lrule Rrule" align="center">9.0 (3.4)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">4.0 h</td>
<td class="Lrule" align="center">11.2 (2.9)</td>
<td class="Lrule Rrule" align="center">6.6 (3.1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">6.0 h</td>
<td class="Lrule" align="center">5.8 (1.6)</td>
<td class="Lrule Rrule" align="center">3.8 (2.5)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">8.0 h</td>
<td class="Lrule" align="center">3.2 (1.0)</td>
<td class="Lrule Rrule" align="center">1.6 (1.3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">12.0 h</td>
<td class="Lrule" align="center">1.1 (0.4)</td>
<td class="Lrule Rrule" align="center">0.5 (0.4)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">C<span class="Sub">max</span>, µg/mL</td>
<td class="Lrule" align="center">15.0 (3.3)</td>
<td class="Lrule Rrule" align="center">13.4 (4.9)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">T<span class="Sub">max</span>, h</td>
<td class="Lrule" align="center">2.6 (0.9)</td>
<td class="Lrule Rrule" align="center">2.0 (1.0)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">AUC, µg∙h/mL</td>
<td class="Lrule" align="center">73.7 (16.0)</td>
<td class="Lrule Rrule" align="center">56.0 (16.9)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">T½, h</td>
<td class="Lrule" align="center">2.4 (0.2)</td>
<td class="Lrule Rrule" align="center">2.0 (0.6)</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center">Total body clearance (CI/F) mL/min/kg</td>
<td class="Lrule" align="center">1.3 (0.3)</td>
<td class="Lrule Rrule" align="center">2.9 (0.7)</td>
</tr>
</tbody>
</table>
<p>The absolute bioavailability of CEDAX Oral Suspension has not been determined. The plasma concentrations of ceftibuten in pediatric patients are dose proportional following single doses of CEDAX Capsules of 200 mg and 400 mg and of CEDAX Oral Suspension between 4.5 mg/kg and 9 mg/kg.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.2"></a><p></p>
<h3>Distribution</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.2.1"></a><p></p>
<h4>CEDAX CAPSULES</h4>
<p class="First">The average apparent volume of distribution (V/F) of ceftibuten in 6 adult subjects is 0.21 L/kg (± 1 SD = 0.03 L/kg).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.2.2"></a><p></p>
<h4>CEDAX ORAL SUSPENSION</h4>
<p class="First">The average apparent volume of distribution (V/F) of ceftibuten in 32 fasting pediatric patients is 0.5 L/kg (± 1 SD = 0.2 L/kg).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.3"></a><p></p>
<h3>Protein Binding</h3>
<p class="First">Ceftibuten is 65% bound to plasma proteins. The protein binding is independent of plasma ceftibuten concentration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.4"></a><p></p>
<h3>Tissue Penetration</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.4.1"></a><p></p>
<h4>Bronchial secretions</h4>
<p class="First">In a study of 15 adults administered a single 400-mg dose of ceftibuten and scheduled to undergo bronchoscopy, the mean concentrations in epithelial lining fluid and bronchial mucosa were 15% and 37%, respectively, of the plasma concentrations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.4.2"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">Sputum</span></h4>
<p class="First">Ceftibuten <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> levels average approximately 7% of the concomitant plasma ceftibuten level. In a study of 24 adults administered ceftibuten 200 mg bid or 400 mg qd, the average C<span class="Sub">max</span> in <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> (1.5 µg/mL) occurred at 2 hours postdose and the average C<span class="Sub">max</span> in plasma (17 µg/mL) occurred at 2 hours postdose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.4.3"></a><p></p>
<h4>Middle-ear fluid (MEF)</h4>
<p class="First">In a study of 12 pediatric patients administered 9 mg/kg, ceftibuten MEF area under the curve (AUC) averaged approximately 70% of the plasma AUC. In the same study, C<span class="Sub">max</span> values were 14.3 ± 2.7 µg/mL in MEF at 4 hours postdose and 14.5 ± 3.7 µg/mL in plasma at 2 hours postdose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.4.4"></a><p></p>
<h4>Tonsillar tissue</h4>
<p class="First">Data on ceftibuten penetration into tonsillar tissue are not available.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.4.5"></a><p></p>
<h4>Cerebrospinal fluid</h4>
<p class="First">Data on ceftibuten penetration into cerebrospinal fluid are not available.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.5"></a><p></p>
<h3>Metabolism and Excretion</h3>
<p class="First">A study with radiolabeled ceftibuten administered to 6 healthy adult male volunteers demonstrated that <span class="Italics">cis</span>-ceftibuten is the predominant component in both plasma and urine. About 10% of ceftibuten is converted to the <span class="Italics">trans</span>-isomer. The <span class="Italics">trans</span>-isomer is approximately ⅛ as antimicrobially potent as the <span class="Italics">cis</span>-isomer.</p>
<p>Ceftibuten is excreted in the urine; 95% of the administered radioactivity was recovered either in urine or feces. In 6 healthy adult male volunteers, approximately 56% of the administered dose of ceftibuten was recovered from urine and 39% from the feces within 24 hours. Because renal excretion is a significant pathway of elimination, patients with renal dysfunction and patients undergoing hemodialysis require dosage adjustment (see <span class="Bold"><a href="#dosage">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="cfood"></a><a name="section-3.1.6"></a><p></p>
<h3>Food Effect on Absorption</h3>
<p class="First">Food affects the bioavailability of ceftibuten from CEDAX Capsules and CEDAX Oral Suspension.</p>
<p>The effect of food on the bioavailability of CEDAX Capsules was evaluated in 26 healthy adult male volunteers who ingested 400 mg of CEDAX Capsules after an overnight fast or immediately after a standardized breakfast. Results showed that food delays the time of C<span class="Sub">max</span> by 1.75 hours, decreases the C<span class="Sub">max</span> by 18%, and decreases the extent of absorption (AUC) by 8%.</p>
<p>The effect of food on the bioavailability of CEDAX Oral Suspension was evaluated in 18 healthy adult male volunteers who ingested 400 mg of CEDAX Oral Suspension after an overnight fast or immediately after a standardized breakfast. Results obtained demonstrated a decrease in C<span class="Sub">max</span> of 26% and an AUC of 17% when CEDAX Oral Suspension was administered with a high-fat breakfast, and a decrease in C<span class="Sub">max</span> of 17% and an AUC of 12% when CEDAX Oral Suspension was administered with a low-calorie nonfat breakfast (see <span class="Bold"><a href="#precau">PRECAUTIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.7"></a><p></p>
<h3>Bioequivalence of Dosage Formulations</h3>
<p class="First">A study in 18 healthy adult male volunteers demonstrated that a 400-mg dose of CEDAX Capsules produced equivalent concentrations to a 400-mg dose of CEDAX Oral Suspension. Average C<span class="Sub">max</span> values were 15.6 (3.1) µg/mL for the capsule and 17.0 (3.2) µg/mL for the suspension. Average AUC values were 80.1 (14.4) µg∙hr/mL for the capsule and 87.0 (12.2) µg∙hr/mL for the suspension.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.8"></a><p></p>
<h3>Special Populations</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.8.1"></a><p></p>
<h4>Geriatric patients</h4>
<p class="First">Ceftibuten pharmacokinetics have been investigated in elderly (65 years of age and older) men (n = 8) and women (n = 4). Each volunteer received ceftibuten 200-mg capsules twice daily for 3½ days. The average C<span class="Sub">max</span> was 17.5 (3.7) µg/mL after 3½ days of dosing compared to 12.9 (2.1) µg/mL after the first dose; ceftibuten accumulation in plasma was 40% at steady state. Information regarding the renal function of these volunteers was not available; therefore, the significance of this finding for clinical use of CEDAX Capsules in elderly patients is not clear. Ceftibuten dosage adjustment in elderly patients may be necessary (see <span class="Bold"><a href="#dosage">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.8.2"></a><p></p>
<h4>Patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span></h4>
<p class="First">Ceftibuten pharmacokinetics have been investigated in adult patients with renal dysfunction. The ceftibuten plasma half-life increased and apparent total clearance (CI/F) decreased proportionately with increasing degree of renal dysfunction. In 6 patients with moderate renal dysfunction (creatinine clearance 30 to 49 mL/min), the plasma half-life of ceftibuten increased to 7.1 hours and CI/F decreased to 30 mL/min. In 6 patients with severe renal dysfunction (creatinine clearance 5 to 29 mL/min), the half-life increased to 13.4 hours and CI/F decreased to 16 mL/min. In 6 functionally anephric patients (creatinine clearance &lt;5 mL/min), the half-life increased to 22.3 hours and CI/F decreased to 11 mL/min (a 7- to 8-fold change compared to healthy volunteers). Hemodialysis removed 65% of the drug from the blood in 2 to 4 hours. These changes serve as the basis for dosage adjustment recommendations in adult patients with mild to severe renal dysfunction (see <span class="Bold"><a href="#dosage">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="section-3.1.9"></a><p></p>
<h3>Microbiology</h3>
<p class="First">Ceftibuten exerts its bactericidal action by binding to essential target proteins of the bacterial cell wall. This binding leads to inhibition of cell-wall synthesis.</p>
<p>Ceftibuten is stable in the presence of most plasmid-mediated beta-lactamases, but it is not stable in the presence of chromosomally-mediated cephalosporinases produced in organisms such as <span class="Italics">Bacteroides, Citrobacter, Enterobacter, Morganella,</span> and <span class="Italics">Serratia.</span> Like other beta-lactam agents, ceftibuten should not be used against <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> resistant to beta-lactams due to general mechanisms such as permeability or penicillin-binding protein changes like penicillin-resistant <span class="Italics">S. pneumoniae.</span></p>
<p>Ceftibuten has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (see <span class="Bold"><a href="#usage">INDICATIONS AND USAGE</a></span>):</p>
<p><span class="Bold Underline">Gram-positive aerobes:</span></p>
<dl>
<dt> </dt>
<dd>
<span class="Italics">Streptococcus pneumoniae</span> (penicillin-susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> only)</dd>
<dt> </dt>
<dd><span class="Italics">Streptococcus pyogenes</span></dd>
</dl>
<p><span class="Bold Underline">Gram-negative aerobes:</span></p>
<dl>
<dt> </dt>
<dd>
<span class="Italics">Haemophilus influenzae</span> (including β-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</dd>
<dt> </dt>
<dd>
<span class="Italics">Moraxella catarrhalis</span> (including β-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</dd>
</dl>
<p>There are no known organisms which are potential pathogens in the indications approved for ceftibuten for which ceftibuten exhibits <span class="Italics">in vitro</span> activity but for which the safety and efficacy of ceftibuten in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these organisms, have not been established in adequate and well-controlled trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Clin-Note"></a><a name="section-3.1.10"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold">NOTE: </span>Ceftibuten is INACTIVE <span class="Italics">in vitro</span> against <span class="Italics">Acinetobacter, Bordetella, Campylobacter, Enterobacter, Enterococcus, Flavobacterium, Hafnia, Listeria, Pseudomonas, Staphylococcus,</span> and <span class="Italics">Streptococcus</span> (except <span class="Italics">pneumoniae</span> and <span class="Italics">pyogenes</span>) species. In addition, it shows little <span class="Italics">in vitro</span> activity against most anaerobes, including most species of <span class="Italics">Bacteroides.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.11"></a><p></p>
<h3>Susceptibility Testing</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.11.1"></a><p></p>
<h4>Dilution Techniques</h4>
<p class="First">Quantitative methods are used to determine antimicrobial minimal inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method (broth, agar, or microdilution) or equivalent with standardized inoculum concentrations and standardized concentrations of ceftibuten powder. The MIC values should be interpreted according to the following criteria when testing <span class="Italics">Haemophilus</span> species using Haemophilus Test Media (HTM):</p>
<table width="70%">
<col align="center" valign="top" width="50%">
<col align="center" valign="top" width="50%">
<thead><tr class="First Last">
<th align="center">MIC (µg/mL)</th>
<th align="center">Interpretation</th>
</tr></thead>
<tbody><tr class="First Last">
<td align="center">≤2</td>
<td align="center">(S) Susceptible</td>
</tr></tbody>
</table>
<p>The current absence of resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> precludes defining any categories other than "Susceptible". <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strains</span> yielding results suggestive of a "Nonsusceptible" category should be submitted to a reference laboratory for further testing.</p>
<p>A report of "Susceptible" implies that an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> due to the <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> may be appropriately treated with the dosage of antimicrobial agent recommended for that type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and infecting species, unless otherwise contraindicated.</p>
<p>Ceftibuten is indicated for penicillin-susceptible only <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Streptococcus pneumoniae.</span> A pneumococcal isolate that is susceptible to penicillin (MIC ≤0.06 µg/mL) can be considered susceptible to ceftibuten for approved indications. Testing of ceftibuten against penicillin-intermediate or penicillin resistant isolates is not recommended. Reliable interpretive criteria for ceftibuten are not currently available. Physicians should be informed that clinical response rates with ceftibuten may be lower in <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> that are not penicillin-susceptible.</p>
<p>Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspect of laboratory procedures. Standard ceftibuten powder should provide the following MIC values:</p>
<table width="70%">
<col align="center" valign="bottom" width="50%">
<col align="center" valign="bottom" width="50%">
<thead><tr class="First Last">
<th align="center">Organism</th>
<th align="center">MIC range (µg/mL)</th>
</tr></thead>
<tbody><tr class="First Last">
<td align="center">
<span class="Italics">Haemophilus influenzae</span><br>ATCC 49247</td>
<td align="center">0.25-1.0</td>
</tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.11.2"></a><p></p>
<h4>Diffusion Techniques</h4>
<p class="First">Quantitative methods that require measurement of zone diameters also provide estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 30 µg of ceftibuten to test the susceptibility of microorganisms to ceftibuten.</p>
<p>Reports from the laboratory providing results of the standard single-disk susceptibility test with a 30-µg ceftibuten disk should be interpreted according to the following criteria when testing <span class="Italics">Haemophilus</span> species using Haemophilus Test Media (HTM):</p>
<table width="70%">
<col align="center" valign="bottom" width="50%">
<col align="center" valign="bottom" width="50%">
<thead><tr class="First Last">
<th align="center">Zone diameter (mm)</th>
<th align="center">Interpretation</th>
</tr></thead>
<tbody><tr class="First Last">
<td align="center">≥28</td>
<td align="center">(S) Susceptible</td>
</tr></tbody>
</table>
<p>The current absence of resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> precludes defining any categories other than "Susceptible". <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strains</span> yielding results suggestive of a "Nonsusceptible" category should be submitted to a reference laboratory for further testing.</p>
<p>Interpretation should be as stated above for results using dilution techniques.</p>
<p>Ceftibuten is indicated for penicillin-susceptible only <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Streptococcus pneumoniae.</span> Pneumococcal isolates with oxacillin zone sizes of ≥20 mm are susceptible to penicillin and can be considered susceptible for approved indications. Reliable disk diffusion tests for ceftibuten do not yet exist.</p>
<p>As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the 30-µg ceftibuten disk should provide the following zone diameters in these laboratory test quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>:</p>
<table width="70%">
<col align="center" valign="bottom" width="50%">
<col align="center" valign="bottom" width="50%">
<thead><tr class="First Last">
<th align="center">Organism</th>
<th align="center">Zone diameter (mm)</th>
</tr></thead>
<tbody><tr class="First Last">
<td align="center">
<span class="Italics">Haemophilus influenzae</span><br>ATCC 49247</td>
<td align="center">29-35</td>
</tr></tbody>
</table>
<p>Cephalosporin-class disks should not be used to test for susceptibility to ceftibuten.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="usage"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">CEDAX (ceftibuten) is indicated for the treatment of individuals with mild-to-moderate <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms in the specific conditions listed below (see <span class="Bold"><a href="#dosage">DOSAGE AND ADMINISTRATION</a></span> and <span class="Bold"><a href="#clins">CLINICAL STUDIES</a></span> sections).</p>
<p><span class="Bold">Acute Bacterial Exacerbations of <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">Chronic Bronchitis</span></span> due to <span class="Italics">Haemophilus influenzae</span> (including β-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">Moraxella catarrhalis</span> (including β-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), or <span class="Italics">Streptococcus pneumoniae</span> (penicillin-susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> only).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="note1"></a><a name="section-4.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">NOTE: </span> In acute bacterial exacerbations of <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span> clinical trials where <span class="Italics">Moraxella catarrhalis</span> was isolated from infected <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> at baseline, ceftibuten clinical efficacy was 22% less than control.</p>
<p><span class="Bold">Acute Bacterial <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span></span> due to <span class="Italics">Haemophilus influenzae</span> (including β-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">Moraxella catarrhalis</span> (including β-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), or <span class="Italics">Streptococcus pyogenes.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="note2"></a><a name="section-4.2"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">NOTE: </span> Although ceftibuten used empirically was equivalent to comparators in the treatment of clinically and/or microbiologically documented acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, the efficacy against <span class="Italics">Streptococcus pneumoniae</span> was 23% less than control. Therefore, ceftibuten should be given empirically <span class="Bold">only</span> when adequate antimicrobial coverage against <span class="Italics">Streptococcus pneumoniae</span> has been previously administered.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> and <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">Tonsillitis</span></span> due to <span class="Italics">Streptococcus pyogenes.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="note3"></a><a name="section-4.3"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">NOTE: </span> Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>. Ceftibuten is generally effective in the eradication of <span class="Italics">Streptococcus pyogenes</span> from the oropharynx; however, data establishing the efficacy of the CEDAX product for the prophylaxis of subsequent <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span> are not available.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">CEDAX (ceftibuten) is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to the cephalosporin group of antibiotics.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warn"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">BEFORE THERAPY WITH THE CEDAX PRODUCT IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> TO CEFTIBUTEN, OTHER CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">PENICILLIN ALLERGY</span>. IF AN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTION</span> TO THE CEDAX PRODUCT OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED.</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> has been reported with nearly all antibacterial agents, including ceftibuten, and may range in severity from mild to life threatening. Therefore, it is important to consider this diagnosis in patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> subsequent to the administration of antibacterial agents.</span></p>
<p>Treatment with antibacterial agents alters normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by <span class="Italics">Clostridium difficile</span> is one primary cause of "antibiotic-associated <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>".</p>
<p>After the diagnosis of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> has been established, appropriate therapeutic measures should be initiated. Mild cases of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against <span class="Italics">Clostridium difficile.</span></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="precau"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">As with other broad-spectrum antibiotics, prolonged treatment may result in the possible emergence and overgrowth of resistant organisms. Careful observation of the patient is essential. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs during therapy, appropriate measures should be taken.</p>
<p>The dose of ceftibuten may require adjustment in patients with varying degrees of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, particularly in patients with creatinine clearance less than 50 mL/min or undergoing hemodialysis (see <span class="Bold"><a href="#dosage">DOSAGE AND ADMINISTRATION</a></span>). Ceftibuten is readily dialyzable. Dialysis patients should be monitored carefully, and administration of ceftibuten should occur immediately following dialysis.</p>
<p>Ceftibuten should be prescribed with caution to individuals with a history of gastrointestinal disease, particularly <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>Information to Patients</h2>
<p class="First">Patients should be informed that:</p>
<ul class="Disc">
<li>If the patient is diabetic, he/she should be informed that CEDAX Oral Suspension contains 1 gram sucrose per teaspoon of suspension.</li>
<li>CEDAX Oral Suspension should be taken at least 2 hours before a meal or at least 1 hour after a meal (see <span class="Bold"><a href="#cfood">CLINICAL PHARMACOLOGY, Food Effect on Absorption</a></span>).</li>
</ul>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.1"></a><p></p>
<h3>Theophylline</h3>
<p class="First">Twelve healthy male volunteers were administered one 200-mg ceftibuten capsule twice daily for 6 days. With the morning dose of ceftibuten on day 6, each volunteer received a single intravenous infusion of theophylline (4 mg/kg). The pharmacokinetics of theophylline were not altered. The effect of ceftibuten on the pharmacokinetics of theophylline administered orally has not been investigated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.2"></a><p></p>
<h3>Antacids or H2-receptor antagonists</h3>
<p class="First">The effect of increased gastric pH on the bioavailability of ceftibuten was evaluated in 18 healthy adult volunteers. Each volunteer was administered one 400-mg ceftibuten capsule. A single dose of liquid antacid did not affect the C<span class="Sub">max</span> or AUC of ceftibuten; however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C<span class="Sub">max </span>by 23% and ceftibuten AUC by 16%. The clinical relevance of these increases is not known.</p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-7.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">There have been no chemical or laboratory test interactions with ceftibuten noted to date. False-positive direct Coombs' tests have been reported during treatment with other cephalosporins. Therefore, it should be recognized that a positive Coombs' test could be due to the drug. The results of assays using red cells from healthy subjects to determine whether ceftibuten would cause direct Coombs' reactions <span class="Italics">in vitro</span> showed no positive reaction at ceftibuten concentrations as high as 40 µg/mL.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term animal studies have not been performed to evaluate the carcinogenic potential of ceftibuten. No mutagenic effects were seen in the following studies: <span class="Italics">in vitro</span> chromosome assay in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, <span class="Italics">in vivo</span> chromosome assay in mouse bone marrow cells, Chinese Hamster Ovary (CHO) cell point mutation assay at the hypoxanthine-guanine phosphoribosyl transferase (HGPRT) locus, and in a bacterial reversion point mutation test (Ames). No impairment of fertility occurred when rats were administered ceftibuten orally up to 2000 mg/kg/day (approximately 43 times the human dose based on mg/m<span class="Sup">2</span>/day).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.6.1"></a><p></p>
<h3>Teratogenic effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6.1.1"></a><p></p>
<h4>Pregnancy Category B</h4>
<p class="First">Ceftibuten was not teratogenic in the pregnant rat at oral doses up to 400 mg/kg/day (approximately 8.6 times the human dose based on mg/m<span class="Sup">2</span>/day). Ceftibuten was not teratogenic in the pregnant rabbit at oral doses up to 40 mg/kg/day (approximately 1.5 times the human dose based on mg/m<span class="Sup">2</span>/day) and has revealed no evidence of harm to the fetus. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-7.7"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">Ceftibuten has not been studied for use during labor and delivery. Its use during such clinical situations should be weighed in terms of potential risk and benefit to both mother and fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether ceftibuten (at recommended dosages) is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ceftibuten is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety and efficacy of ceftibuten in infants less than 6 months of age has not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.10"></a><p></p>
<h2>Geriatric Patients</h2>
<p class="First">The usual adult dosage recommendation may be followed for patients in this age group. However, these patients should be monitored closely, particularly their renal function, as dosage adjustment may be required.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE EVENTS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>Clinical Trials</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1"></a><p></p>
<h3>CEDAX CAPSULES (adult patients)</h3>
<p class="First">In clinical trials, 1728 adult patients (1092 US and 636 international) were treated with the recommended dose of ceftibuten capsules (400 mg per day). There were no <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> or permanent disabilities thought due to <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">drug toxicity</span> in any of the patients in these studies. Thirty-six of 1728 (2%) patients discontinued medication due to adverse events thought by the investigators to be possibly, probably, or almost certainly related to <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">drug toxicity</span>. The discontinuations were primarily for <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span>, usually <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. Six of 1728 (0.3%) patients were discontinued due to <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> thought related to ceftibuten administration.</p>
<p>In the US trials, the following adverse events were thought by the investigators to be possibly, probably, or almost certainly related to ceftibuten capsules in multiple-dose clinical trials (n = 1092 ceftibuten-treated patients).</p>
<table width="85%">
<col align="center" valign="top" width="40%">
<col align="center" valign="top" width="40%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last"><th class="Lrule Rrule" align="center" colspan="3">ADVERSE REACTIONS  <br>CEFTIBUTEN CAPSULES <br>US CLINICAL TRIALS IN ADULT PATIENTS (n = 1092)</th></tr></thead>
<tbody>
<tr class="First">
<td class="Lrule" align="center" rowspan="2">Incidence equal to or greater than 1%</td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Lrule Rrule" align="center">4%</td>
</tr>
<tr>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Lrule Rrule" align="center">3%</td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Lrule Rrule" align="center">3%</td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Lrule Rrule" align="center">2%</td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Lrule Rrule" align="center">1%</td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td class="Lrule Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Lrule Rrule" align="center">1%</td>
</tr>
<tr>
<td class="Lrule" align="center" rowspan="2">Incidence less than 1% but greater than 0.1%</td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">Eructation</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Loose stools</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Moniliasis</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal congestion</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste perversion</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginitis</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
</tbody>
</table>
<table width="85%">
<col align="center" valign="top" width="40%">
<col align="center" valign="top" width="40%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last"><th class="Lrule Rrule" align="center" colspan="3">LABORATORY VALUE CHANGES<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a><br>CEFTIBUTEN CAPSULES <br>US CLINICAL TRIALS IN ADULT PATIENTS</th></tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Changes in laboratory values with possible clinical significance regardless of whether or not the investigator thought that the change was due to <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">drug toxicity</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="center" rowspan="2">Incidence equal to or greater than 1%</td>
<td class="Lrule" align="center">↑ BUN</td>
<td class="Lrule Rrule" align="center">4%</td>
</tr>
<tr>
<td class="Lrule" align="center">↑ Eosinophils</td>
<td class="Lrule Rrule" align="center">3%</td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center">↓ Hemoglobin</td>
<td class="Lrule Rrule" align="center">2%</td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center">↑ ALT (SGPT)</td>
<td class="Lrule Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center">↑ Bilirubin</td>
<td class="Lrule Rrule" align="center">1%</td>
</tr>
<tr>
<td class="Lrule" align="center" rowspan="2">Incidence less than 1% but greater than 0.1%</td>
<td class="Lrule" align="center">↑ Alk phosphatase</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center">↑ Creatinine</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center">↑ Platelets</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center">↓ Platelets</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center">↓ Leukocytes</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center">↑ AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>)</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.2"></a><p></p>
<h3>CEDAX ORAL SUSPENSION (pediatric patients)</h3>
<p class="First">In clinical trials, 1152 pediatric patients (772 US and 380 international), 97% of whom were younger than 12 years of age, were treated with the recommended dose of ceftibuten (9 mg/kg once daily up to a maximum dose of 400 mg per day) for 10 days. There were no <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, life-threatening adverse events, or permanent disabilities in any of the patients in these studies. Eight of 1152 (&lt;1%) patients discontinued medication due to adverse events thought by the investigators to be possibly, probably, or almost certainly related to <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">drug toxicity</span>. The discontinuations were primarily (7 out of 8) for <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span>, usually <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. One patient was discontinued due to a cutaneous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> thought possibly related to ceftibuten administration.</p>
<p>In the US trials, the following adverse events were thought by the investigators to be possibly, probably, or almost certainly related to ceftibuten oral suspension in multiple-dose clinical trials (n = 772 ceftibuten-treated patients).</p>
<table width="85%">
<col align="center" valign="top" width="40%">
<col align="center" valign="top" width="40%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last"><th class="Lrule Rrule" align="center" colspan="3">ADVERSE REACTIONS  <br>CEFTIBUTEN ORAL SUSPENSION <br>US CLINICAL TRIALS IN PEDIATRIC PATIENTS (n = 772)</th></tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>NOTE: The incidence of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> in pediatric patients ≤2 years old was 8% (23/301) compared with 2% (9/471) in pediatric patients &gt;2 years old.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="center" rowspan="2">Incidence equal to or greater than 1%</td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</td>
<td class="Lrule Rrule" align="center">4%</td>
</tr>
<tr>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Lrule Rrule" align="center">2%</td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td class="Lrule Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Loose stools</span></td>
<td class="Lrule Rrule" align="center">2%</td>
</tr>
<tr>
<td class="Lrule" align="center" rowspan="2">Incidence less than 1% but greater than 0.1%</td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center">Diaper <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">Hyperkinesia</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritability</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Rigors</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
</tbody>
</table>
<table width="85%">
<col align="center" valign="top" width="40%">
<col align="center" valign="top" width="40%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last"><th class="Lrule Rrule" align="center" colspan="3">LABORATORY VALUE CHANGES<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a><br>CEFTIBUTEN ORAL SUSPENSION <br>US CLINICAL TRIALS IN ADULT PATIENTS</th></tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Changes in laboratory values with possible clinical significance regardless of whether or not the investigator thought that the change was due to <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">drug toxicity</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="center" rowspan="3">Incidence equal to or greater than 1%</td>
<td class="Lrule" align="center">↑ Eosinophils</td>
<td class="Lrule Rrule" align="center">3%</td>
</tr>
<tr>
<td class="Lrule" align="center">↑ BUN</td>
<td class="Lrule Rrule" align="center">2%</td>
</tr>
<tr>
<td class="Lrule" align="center">↓ Hemoglobin</td>
<td class="Lrule Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center">↑ Platelets</td>
<td class="Lrule Rrule" align="center">1%</td>
</tr>
<tr>
<td class="Lrule" align="center" rowspan="3">Incidence less than 1% but greater than 0.1%</td>
<td class="Lrule" align="center">↑ ALT (SGPT)</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center">↑ AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>)</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center">↑ Alk phosphatase</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center">↑ Platelets</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center">↑ Bilirubin</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center">↑ Creatinine</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>In Post-marketing Experience</h2>
<p class="First">The following adverse experiences have been reported during worldwide post-marketing surveillance: <span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">aphasia</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>-like reactions, <span class="product-label-link" type="condition" conceptid="253321" conceptname="Stridor">stridor</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2>Cephalosporin-class Adverse Reactions</h2>
<p class="First">In addition to the adverse reactions listed above that have been observed in patients treated with ceftibuten capsules, the following adverse events and altered laboratory tests have been reported for cephalosporin-class antibiotics:</p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, renal dysfunction, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">toxic nephropathy</span>, hepatic <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, false-positive test for urinary glucose, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>. <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span>; onset of symptoms may occur during or after antibiotic treatment (see <span class="Bold"><a href="#warn">WARNINGS</a></span>).</dd>
</dl>
<p>Several cephalosporins have been implicated in triggering <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, particularly in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> when the dosage was not reduced (see <span class="Bold"><a href="#dosage">DOSAGE AND ADMINISTRATION</a></span> and <span class="Bold"><a href="#over">OVERDOSAGE</a></span>). If <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="over"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Overdosage of cephalosporins can cause cerebral irritation leading to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. Ceftibuten is readily dialyzable and significant quantities (65% of plasma concentrations) can be removed from the circulation by a single hemodialysis session. Information does not exist with regard to removal of ceftibuten by peritoneal dialysis.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="dosage"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended doses of CEDAX Oral Suspension are presented in the table below. <span class="Bold">CEDAX Oral Suspension must be administered at least 2 hours before or 1 hour after a meal</span>.
						</p>
<table width="85%">
<col align="left" valign="bottom" width="50%">
<col align="center" valign="bottom" width="15%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="15%">
<thead><tr class="First Last">
<th class="Lrule" align="left">Type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (as qualified in the <a href="#usage">INDICATIONS AND USAGE</a> section of this labeling)</th>
<th class="Lrule" align="center">Daily Maximum Dose</th>
<th class="Lrule" align="center">Dose and Frequency</th>
<th class="Lrule Rrule" align="center">Duration</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule" align="left"><span class="Underline">ADULTS (12 years of age and older):</span></td>
<td class="Lrule" align="center">400 mg</td>
<td class="Lrule" align="center">400 mg QD</td>
<td class="Lrule Rrule" align="center">10 days</td>
</tr>
<tr>
<td class="Lrule" align="left">Acute Bacterial Exacerbations of <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">Chronic Bronchitis</span> due to <span class="Italics">H. influenzae</span> (including β-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">M. catarrhalis</span> (including β-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), or <span class="Italics">Streptococcus pneumoniae</span> (penicillin-susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> only). (See <span class="Bold"><a href="#note1">INDICATIONS AND USAGE - NOTE</a></span>.)</td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> and <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> due to <span class="Italics">S. pyogenes</span>. Acute Bacterial <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span> due to <span class="Italics">H. influenzae</span> (including β-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">M. catarrhalis</span> (including β-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), or <span class="Italics">S. pyogenes</span>. (See <span class="Bold"><a href="#note2">INDICATIONS AND USAGE - NOTE</a></span>.)</td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Underline">PEDIATRIC PATIENTS:</span></td>
<td class="Lrule" align="center">400 mg</td>
<td class="Lrule" align="center">9 mg/kg QD</td>
<td class="Lrule Rrule" align="center">10 days</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> and <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> due to <span class="Italics">S. pyogenes</span>. Acute Bacterial <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span> due to <span class="Italics">H. influenzae</span> (including β-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), and <span class="Italics">M. catarrhalis</span> (including β-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), or <span class="Italics">S. pyogenes</span>. (See <span class="Bold"><a href="#note3">INDICATIONS AND USAGE - NOTE</a></span>.)</td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
</tbody>
</table>
<table width="80%">
<col align="center" valign="top" width="50%">
<col align="center" valign="top" width="50%">
<thead><tr class="First Last"><th class="Lrule Rrule" align="center" colspan="2">CEFTIBUTEN ORAL SUSPENSION <br>PEDIATRIC DOSAGE CHART</th></tr></thead>
<tbody>
<tr class="Botrule First">
<th class="Lrule" align="center">CHILD'S WEIGHT</th>
<th class="Lrule Rrule" align="center">90 mg/5 mL</th>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">10 kg 22 lbs</td>
<td class="Lrule Rrule" align="center">1 tsp QD</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">20 kg 44 lbs</td>
<td class="Lrule Rrule" align="center">2 tsp QD</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center">40 kg 88 lbs</td>
<td class="Lrule Rrule" align="center">4 tsp QD</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Pediatric patients weighing more than 45 kg should receive the maximum daily dose of 400 mg.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">CEDAX Capsules and CEDAX Oral Suspension may be administered at normal doses in the presence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> with creatinine clearance of 50 mL/min or greater. The recommendations for dosing in patients with varying degrees of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> are presented in the following table.</p>
<table width="80%">
<col align="center" valign="middle" width="40%">
<col align="center" valign="middle" width="60%">
<thead><tr class="First Last">
<th class="Lrule" align="center">Creatinine <br>Clearance <br>(mL/min)</th>
<th class="Lrule Rrule" align="center">Recommended Dosing Schedules</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="center" valign="top">&gt;50</td>
<td class="Lrule Rrule" align="center">9 mg/kg or 400 mg Q24h <br>(normal dosing schedule)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">30-49</td>
<td class="Lrule Rrule" align="center">4.5 mg/kg or 200 mg Q24h</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center">5-29</td>
<td class="Lrule Rrule" align="center">2.25 mg/kg or 100 mg Q24h</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Hemodialysis Patients</h2>
<p class="First">In patients undergoing hemodialysis two or three times weekly, a single 400-mg dose of ceftibuten capsules or a single dose of 9 mg/kg (maximum of 400 mg of ceftibuten) oral suspension may be administered at the end of each hemodialysis session.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3"></a><p></p>
<h2>Directions for Mixing CEDAX Oral Suspension</h2>
<table width="80%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="middle" width="10%">
<col align="left" valign="bottom" width="30%">
<col align="left" valign="bottom" width="40%">
<thead>
<tr class="First"><th class="Botrule Lrule Rrule" align="center" colspan="4">DIRECTIONS FOR MIXING CEDAX ORAL SUSPENSION</th></tr>
<tr class="Last">
<th class="Lrule" align="center">Final <br>Concentration</th>
<th class="Lrule" align="center">Bottle Size</th>
<th class="Lrule" align="left">Amount of Water</th>
<th class="Lrule Rrule" align="left">Directions</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule" align="center"></td>
<td class="Botrule Lrule" align="center">60 mL</td>
<td class="Botrule Lrule" align="left">Suspend in 53 mL of water</td>
<td class="Botrule Lrule Rrule" align="left" rowspan="3" valign="middle">First tap the bottle to loosen powder. Then add water in two portions, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> well after each aliquot.</td>
</tr>
<tr>
<td class="Lrule" align="center">90 mg per 5 mL</td>
<td class="Botrule Lrule" align="center">90 mL</td>
<td class="Botrule Lrule" align="left">Suspend in 78 mL of water</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center">120 mL</td>
<td class="Botrule Lrule" align="left">Suspend in 103 mL of water</td>
</tr>
</tbody>
</table>
<p class="First">After mixing, the suspension may be kept for 14 days and must be stored in the refrigerator. Keep tightly closed. Shake well before each use. Discard any unused portion after 14 days.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">CEDAX Capsules, containing 400 mg of ceftibuten (as ceftibuten dihydrate) are white, opaque capsules imprinted with the product name and strength, are available as follows:</p>
<dl>
<dt> </dt>
<dd>20 Capsules/Bottle (NDC 59630-820-20)</dd>
</dl>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Store the capsules between 2° and 25°C (36° and 77°F).</span> Replace cap securely after each opening.</p>
<p>CEDAX Oral Suspension is an off-white to cream-colored powder that, when reconstituted as directed, contains ceftibuten equivalent to 90 mg/5 mL, supplied as follows:</p>
<p><span class="Bold">90 mg/5 mL</span></p>
<table width="60%">
<col align="left" valign="top" width="20%">
<col align="right" valign="top" width="30%">
<col align="center" valign="top" width="50%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left">18 mg/mL</td>
<td align="right">60-mL Bottle</td>
<td align="center">(NDC 59630-821-60)</td>
</tr>
<tr>
<td align="left">18 mg/mL</td>
<td align="right">90-mL Bottle</td>
<td align="center">(NDC 59630-821-90)</td>
</tr>
<tr class="Botrule Last">
<td align="left">18 mg/mL</td>
<td align="right">120-mL Bottle</td>
<td align="center">(NDC 59630-821-12)</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Prior to reconstitution, the powder must be stored between 2° and 25°C (36° and 77°F). Once it is reconstituted, the oral suspension is stable for 14 days when stored in the refrigerator between 2° and 8°C (36° and 46°F).</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="clins"></a><a name="section-12"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1"></a><p></p>
<h2>Acute Bacterial Exacerbations of <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">Chronic Bronchitis</span></h2>
<p class="First">Three clinical trials (two domestic, the third abroad) have been conducted testing ceftibuten in the treatment of acute exacerbations of <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span> (AECB). Overall, the clinical outcome among patients who had signs and symptoms of AECB, who had a gram stain showing a predominance of PMNs and few epithelial cells, and who were evaluated at approximately 1 to 2 weeks after completing therapy were equivalent to comparators. The bacterial eradication rates of specific pathogens are presented below.</p>
<table width="90%">
<col align="left" valign="bottom" width="10%">
<col align="left" valign="bottom" width="30%">
<col align="center" valign="bottom" width="30%">
<col align="center" valign="bottom" width="30%">
<thead>
<tr class="First"><th align="center" colspan="4">BACTERIOLOGICAL OUTCOME<br>ACUTE BACTERIAL EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">CHRONIC BRONCHITIS</span></th></tr>
<tr class="Last">
<th align="left"></th>
<th align="left"></th>
<th align="center">Ceftibuten 400 mg QD</th>
<th align="center">Control</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left" colspan="2">Bacteriological Eradication Rates</td>
<td align="center"></td>
<td align="center"></td>
<td></td>
</tr>
<tr>
<td align="left"></td>
<td align="left"><span class="Italics">Haemophilus influenzae</span></td>
<td align="center">45/62 (73%)</td>
<td align="center">26/36 (72%)</td>
</tr>
<tr>
<td align="left"></td>
<td align="left"><span class="Italics">H. parainfluenzae</span></td>
<td align="center">10/10           </td>
<td align="center">4/6           </td>
</tr>
<tr>
<td align="left"></td>
<td align="left"><span class="Italics">Moraxella catarrhalis</span></td>
<td align="center">33/46 (72%)</td>
<td align="center">32/34 (94%)</td>
</tr>
<tr class="Last">
<td align="left"></td>
<td align="left"><span class="Italics">Streptococcus pneumoniae</span></td>
<td align="center">23/35 (66%)</td>
<td align="center">14/20 (70%)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2"></a><p></p>
<h2>Acute Bacterial <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span></h2>
<p class="First">Four clinical trials (three domestic, the fourth abroad) have been conducted testing ceftibuten in the treatment of acute bacterial <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>. Overall, the clinical outcome among patients who had signs and symptoms of acute bacterial <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> and who were evaluated at approximately 1 to 2 weeks after completing therapy were equivalent to comparators. Tympanocentesis was performed on patients in three of the above-mentioned studies; the bacterial eradication rates of specific pathogens are presented below.</p>
<table width="90%">
<caption><span></span></caption>
<col align="left" valign="bottom" width="10%">
<col align="left" valign="bottom" width="30%">
<col align="center" valign="bottom" width="30%">
<col align="center" valign="bottom" width="30%">
<thead>
<tr class="First"><th align="center" colspan="4">BACTERIOLOGICAL OUTCOME<br>ACUTE BACTERIAL <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">OTITIS MEDIA</span></th></tr>
<tr class="Last">
<th align="left"></th>
<th align="left"></th>
<th align="center">Ceftibuten 9 mg/kg QD</th>
<th align="center">Control</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left" colspan="2">Bacteriological Eradication Rates</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"></td>
<td align="left"><span class="Italics">Haemophilus influenzae</span></td>
<td align="center">56/67    (81%)</td>
<td align="center">29/38 (76%)</td>
</tr>
<tr>
<td align="left"></td>
<td align="left"><span class="Italics">Moraxella catarrhalis</span></td>
<td align="center">20/26    (77%)</td>
<td align="center">13/17 (77%)</td>
</tr>
<tr>
<td align="left"></td>
<td align="left"><span class="Italics">Streptococcus pneumoniae</span></td>
<td align="center">68/105 (65%)</td>
<td align="center">35/40 (88%)</td>
</tr>
<tr class="Last">
<td align="left"></td>
<td align="left"><span class="Italics">Streptococcus pyogenes</span></td>
<td align="center">13/15    (87%)</td>
<td align="center">5/5           </td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-13"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically – Third Edition. Approved Standard NCCLS Document M7-A3, Vol. 13, No. 25, NCCLS, Villanova, PA. December, 1993.</li>
<li>National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests – Fifth Edition. Approved Standard NCCLS Document M2-A5, Vol. 13, No. 24, NCCLS, Villanova, PA. December, 1993.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Sciele™<br>Pharma, Inc.<br>A SHIONOGI COMPANY</span></p>
<p>For inquires call 1-800-849-9707 ext. 1454</p>
<p>Sciele Pharma, Inc., Atlanta, GA 30328<br>Manufactured by Schering Corporation CED01PIB02<br>Distributed by Sciele Pharma, Inc.</p>
<p>Rev. 06/09</p>
<p>B-33605501<br><span class="Bold">25014456T</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 400 mg Capsule Label</h1>
<p class="First"><span class="Bold">NDC</span> 59630-820-20</p>
<p><span class="Bold">CEDAX</span><span class="Sup">®</span><br><span class="Bold">(ceftibuten<br>capsules)</span></p>
<p><span class="Bold">400 mg</span></p>
<p><span class="Bold">For Oral Administration</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">20 Capsules</span></p>
<p><span class="Bold">Sciele™ <br>Pharma, Inc.<br>A SHIONOGI COMPANY</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 400 mg Capsule Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2dd58c88-142f-41ad-bc31-0a4fff074970&amp;name=cedax-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 60 mL Carton</h1>
<p class="First"><span class="Bold">NDC</span> 59630-821-60</p>
<p><span class="Bold">CEDAX</span><span class="Sup">®</span><br><span class="Bold">(ceftibuten for <br>oral suspension)</span></p>
<p><span class="Bold">90 <br>mg per 5 mL</span></p>
<p><span class="Bold">60 mL (when reconstituted)</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">Sciele™ <br>Pharma, Inc.<br>A SHIONOGI COMPANY</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 60 mL Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2dd58c88-142f-41ad-bc31-0a4fff074970&amp;name=cedax-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 90 mL Carton</h1>
<p class="First"><span class="Bold">NDC</span> 59630-821-90</p>
<p><span class="Bold">CEDAX</span><span class="Sup">®</span><br><span class="Bold">(ceftibuten for <br>oral suspension)</span></p>
<p><span class="Bold">90 <br>mg per 5 mL</span></p>
<p><span class="Bold">90 mL (when reconstituted)</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">Sciele™ <br>Pharma, Inc.<br>A SHIONOGI COMPANY</span></p>
<p><span class="Bold"></span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 90 mL Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2dd58c88-142f-41ad-bc31-0a4fff074970&amp;name=cedax-04.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 120 mL Carton</h1>
<p class="First"><span class="Bold">NDC</span> 59630-821-12</p>
<p><span class="Bold">CEDAX</span><span class="Sup">®</span><br><span class="Bold">(ceftibuten for <br>oral suspension)</span></p>
<p><span class="Bold">90 <br>mg per 5 mL</span></p>
<p><span class="Bold">120 mL (when reconstituted)</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">Sciele™ <br>Pharma, Inc.<br>A SHIONOGI COMPANY</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 120 mL Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2dd58c88-142f-41ad-bc31-0a4fff074970&amp;name=cedax-05.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEDAX 		
					</strong><br><span class="contentTableReg">ceftibuten dihydrate capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:59630-820</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Ceftibuten dihydrate</strong> (Ceftibuten) </td>
<td class="formItem">Ceftibuten dihydrate</td>
<td class="formItem">400 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>benzyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium propionate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>edetate calcium disodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>butylparaben</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>propylparaben</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>methylparaben</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (opaque) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">0mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">CEDAX;400;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:59630-820-20</td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050685</td>
<td class="formItem">12/20/1995</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEDAX 		
					</strong><br><span class="contentTableReg">ceftibuten dihydrate suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:59630-821</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Ceftibuten dihydrate</strong> (Ceftibuten) </td>
<td class="formItem">Ceftibuten dihydrate</td>
<td class="formItem">18 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sucrose</strong></td>
<td class="formItem">1 g  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium benzoate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>xanthan gum</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (off-white to cream) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">FREEFORM (powder) </td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">CHERRY</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:59630-821-60</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">60 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:59630-821-90</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">90 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:59630-821-12</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">120 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050686</td>
<td class="formItem">12/20/1995</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Sciele Pharma, Inc.
							(802728477)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 1/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d1672f05-b1ee-40f9-9b4c-7ba2fad264fc</div>
<div>Set id: 2dd58c88-142f-41ad-bc31-0a4fff074970</div>
<div>Version: 1</div>
<div>Effective Time: 20100112</div>
</div>
</div> <div class="DistributorName">Sciele Pharma, Inc.</div></p>
</body></html>
